Mycoplasma Plate Antigens Market

By Product Type;

Plate Agglutination Test Products (Mycoplasma Plate Antigens, Mycoplasma Plate Antigens - Control Serum, and Plate Antigens - Negative Control Serum) and Confirmatory Testing Reagents (Mycoplasma Whole Organism, Mycoplasma Antiserum, and Negative Serum)

By Applications;

Drug Development, Infection Medicine, Veterinary Research, and Others

By End User;

Veterinary Hospitals, Poultry Veterinary Clinics, Academic & Research Institutes, and Pharma & Biotech Companies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn747653509 Published Date: June, 2025 Updated Date: August, 2025

Mycoplasma Plate Antigens Market Overview

Mycoplasma Plate Antigens Market (USD Million)

Mycoplasma Plate Antigens Market was valued at USD 603.82 million in the year 2024. The size of this market is expected to increase to USD 915.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.1%.


Mycoplasma Plate Antigens Market

*Market size in USD million

CAGR 6.1 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.1 %
Market Size (2024)USD 603.82 Million
Market Size (2031)USD 915.13 Million
Market ConcentrationMedium
Report Pages354
603.82
2024
915.13
2031

Major Players

  • Charles River
  • Prospec-Tany Technogene Ltd
  • Abnova Corporation
  • Qiagen N.V.
  • MyBiosource, Inc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Mycoplasma Plate Antigens Market

Fragmented - Highly competitive market without dominant players


The Mycoplasma Plate Antigens Market is expanding significantly as laboratories and diagnostic centers seek high‑precision tools for Mycoplasma detection in cultures, with usage rising by over 40%. These plate antigens provide specific immune-based detection methods, reducing contamination risks in cell cultures and biologics manufacturing. Providers are employing focused growth strategies to meet rising demand for reliable assay platforms. Enhanced collaboration between diagnostic reagent companies and research labs is accelerating adoption and supporting overall market expansion.

Technological Advancements Enhancing Assay Performance
Recent innovations in antigen formulation and assay sensitivity have improved detection accuracy by over 35%. These technological advancements enable faster turnaround and reduce false positives, strengthening quality control protocols. Continuous innovation is being seen in more stable antigen preparations and simplified assay formats. Strategic partnerships with biotech firms and cell culture facilities are enhancing product reach, fostering broader market expansion.

Wider Adoption in Research and Biomanufacturing Sectors
Use of Mycoplasma plate antigen testing has grown by over 42% across cell culture labs, biologics manufacturers, and research institutions. Its adoption supports routine screening protocols and contamination prevention measures. Companies are implementing targeted growth strategies by offering standardized reagent kits and training support. Through active partnerships with biopharma and academic centers, market expansion is being realized across diverse end‑user environments.

Future Outlook Focused on Standardization and Automation
Over 44% of developers are integrating automated assay processing and highly standardized antigen kits into their portfolios, reinforcing the market’s future outlook. Ongoing innovation in assay automation, kit stability, and cross‑reactivity reduction is enhancing product usability. Companies are pursuing precise expansion strategies by embedding testing solutions into automated quality control workflows. These advancements position the market for long‑term expansion in regulated cell culture and biomanufacturing settings.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product Type
    2. Market Snapshot, By Applications
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Mycoplasma Plate Antigens Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Biopharmaceutical Production
        2. Stringent Regulatory Requirements
        3. Rising R&D Investments
        4. Growing Awareness
        5. Technological Advancements
      2. Restraints
        1. High Cost Factors
        2. Limited Regulatory Clarity
        3. Complex Manufacturing Processes
        4. Variability in Test Results
        5. Lack of Skilled Personnel
      3. Opportunities
        1. Untapped Emerging Markets
        2. Strategic Partnerships
        3. Advancements in Automation
        4. Customized Solutions Demand
        5. Patent Expirations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Mycoplasma Plate Antigens Market, By Product Type, 2021 - 2031 (USD Million)
      1. Plate Agglutination Test Products
        1. Mycoplasma Plate Antigens
        2. Mycoplasma Plate Antigens- Control Serum
        3. Plate Antigens -Negative Control Serum
      2. Confirmatory Testing Reagents
        1. Mycoplasma Whole Organism
        2. Mycoplasma Antiserum
        3. Negative serum
    2. Mycoplasma Plate Antigens Market, By Applications, 2021 - 2031 (USD Million)
      1. Drug Development
      2. Infection Medicine
      3. Veterinary Research
      4. Others
    3. Mycoplasma Plate Antigens Market, By End User, 2021 - 2031 (USD Million)
      1. Veterinary Hospitals
      2. Poultry Veterinary Clinics
      3. Academic & Research Institutes
      4. Pharma & Biotech Companies
    4. Mycoplasma Plate Antigens Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Charles River
      2. Prospec-Tany Technogene Ltd
      3. Abnova Corporation
      4. Qiagen N.V.
      5. MyBiosource, Inc.
  7. Analyst Views
  8. Future Outlook of the Market